Introduction
The Notch pathway plays a key role in regulating cell fate decisions in normal development and in many cancer types. Notch1 is the most studied of four receptors (Notch 1-4) and its deregulation can lead to changes in cancer-relevant functions such as proliferation, stemness, epithelial-mesenchymal transition, and angiogenesis [1] . Subsequent to ligand binding, Notch proteins ultimately undergo cleavage by the gamma-secretase complex, which releases the Notch intracellular domain (NICD) to migrate to the nucleus and activate transcription of Notch target genes [1] .
Brontictuzumab (OMP-52M51) is a full-length IgG 2 humanized monoclonal antibody that selectively binds the Notch1 juxtamembrane negative regulatory region (NRR) and inhibits signaling by stabilizing its quiescence irrespective of the ligand. Notch1 is activated by oncogenic mutations in a variety of hematologic and epithelial tumors such as T-cell acute lymphoblastic leukemia (T-ALL) [2] , breast cancer [3] , and adenoid cystic carcinoma (ACC) [4] . Most NOTCH1 activating mutations are located in the NRR, which leads to ligand-independent receptor proteolysis, or in the PEST domain, which prevents rapid degradation of the cleaved receptor [1] . Other mechanisms of Notch1 activation include overexpression of functional Notch ligands (DLL 1, 4 and JAG 1, 2), mutations in negative regulators of NICD stability (e.g. FBXW7), and up-regulation by miRNAdependent epigenetic events [1] .
Notch1 has pleiotropic roles and can function as an oncogene or tumor suppressor, depending on the cellular context, highlighting the importance of tumor selection in the clinical development of Notch1 inhibitors. Furthermore, different Notch family members carry out distinct functions, sometimes opposing, therefore, targeting other members of the Notch family might not be of therapeutic interest [5, 6] . Pan-notch inhibitors such as gamma-secretase inhibitors (GSIs) are currently in clinical development; however, their applicability has been limited mainly due to significant ontarget toxicity, particularly diarrhea induced by Notch inhibition in the intestinal crypts [7] . Brontictuzumab specifically inhibits Notch1, therefore potentially mitigating significant intestinal toxicity. Brontictuzumab has shown tumor growth inhibition in various patient-derived xenograft models and it caused only mild goblet cell metaplasia compared with severe metaplasia in mice treated with GSI [8] .
The primary objective of this first-in-human study was to determine the maximum tolerated dose (MTD) of brontictuzumab in selected solid tumors. Secondary objectives included safety, pharmacokinetics (PK), immunogenicity, and preliminary efficacy analysis.
Patients and methods

Patient eligibility
Eligible patients were !18 years old and had advanced, selected solid tumors with no additional standard treatment available. Tumor types were selected based on two criteria: (i) tumors bearing NOTCH1 mutation in the NRR or PEST domain or (ii) tumors with a high frequency of Notch1 pathway activation (!12%) as defined by an immunohistochemistry (IHC) assay for NICD1 as detailed in 'Biomarker Assessment.' It included breast cancer, cholangiocarcinoma, colorectal cancer (CRC), esophageal cancer, gastric cancer, pancreatic cancer, small-cell lung cancer, and ACC. In the dose expansion phase, evidence of Notch1 pathway activation by NICD1 IHC positivity was required for study entry. Additional inclusion criteria included measurable or evaluable disease per RECIST 1.1, ECOG performance status of 0-1, adequate organ and hematologic function, and no endobronchial lesions or lesions infiltrating major vessels (due to antiangiogenic effect of Notch1 inhibition). Exclusion criteria included history of other malignancies in remission <3 years, or current clinically significant gastrointestinal or liver disease.
All patients provided written informed consent, and local ethics committee approval was obtained. The study was conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki.
Study design and treatment
This was a multicenter, open-label, phase I study of brontictuzumab in subjects with certain relapsed or refractory solid tumors. The study included a dose escalation and an expansion phase. Dose escalation was conducted using an accelerated titration approach such that in each cohort, a minimum of one subject was enrolled and dose escalation to the next level was allowed provided no grade 2 study drug-related or doselimiting toxicities (DLTs) were observed. If two or more subjects experienced grade ! 2 study drug-related toxicity, or one or more subjects experienced DLT, then dose escalation was switched to a 3 þ 3 schema. The MTD was defined as the highest dose level where less than two of six assessable subjects experienced DLTs. DLT was defined as any ! grade 3 drug-related adverse event (AE) that occurred from days 0-28 for once every-4-week (Q4W) dosing and days 0-21 for once every-3-week (Q3W) schedule. Exceptions included grade 3 hypertension controlled with oral antihypertensives, grade 3 infusion reactions that resolved within 24 h, grade 3 diarrhea, nausea, and/or vomiting that responded to standard medical treatment within 48 h, and grade 3 electrolyte disturbances that responded to correction within 24 h.
The planned brontictuzumab dose levels were 0.25, 0.5, 1, and 2.5 mg/ kg administered intravenously over 30 min Q4W and 2.5 mg/kg Q3W. Additional cohorts at 1, 1.5, and 2 mg/kg Q3W were opened during dose escalation. Dose adjustments were not permitted within a cohort; however, subjects who experienced a DLT due to diarrhea could continue dosing at one dose level below once the diarrhea resolved. Following identification of the MTD, subjects were enrolled into an expansion cohort and dosed at the MTD.
Safety and efficacy assessments
Medical history and demographics were collected at screening. Vital signs, weight, physical examination, CBC, and serum chemistry were carried out weekly from days 0-70, then every 2 or 3 weeks for Q4W and Q3W schedules, respectively. Efficacy was evaluated by overall response rate as per RECIST 1.1; progression-free survival (PFS) and overall survival (OS), measured from treatment initiation to the event; and duration of response (DOR), calculated from the first response until disease progression or death. The first response assessment occurred at day 70. Subsequent assessments occurred every 8 weeks for Q4W or every 9 weeks for Q3W dosing. Treatment-emergent adverse events (TEAEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 on an ongoing basis. Guidelines for management of diarrhea were provided in the protocol as follows: subjects with ! grade 2 diarrhea should receive loperamide 4 mg orally following the first loose stool, followed by 2 mg after every unformed stool (maximum 16 mg/day). If grade 3 diarrhea develops, loperamide should be discontinued and second-line therapy should start (i.e. lomotil 2 tablets 4Â/day and/or octreotide 100-150 lg SQ 3Â/day up to 500 lg 3Â/day and/or tincture of opium per institution guidelines). Corticosteroids were allowed in patients that have developed diarrhea in preceding cycles.
Pharmacokinetics and immunogenicity
Serum samples were obtained for PK analyses from all subjects at various time-points. Samples were analyzed with an enzyme-linked immunosorbent assay coated with human Notch1 fused with rabbit Fc and detected with mouse antihuman IgG. A description of the PK parameters obtained is available in Supplementary Material, available at Annals of Oncology online.
Immunogenicity was evaluated by determining antidrug antibody (ADA) positivity in serum samples at multiple time points. Antibodies against brontictuzumab were measured using an electrochemiluminescent immunoassay method (MSD technology). The relative assay sensitivity was 13-24 ng/ml of antibrontictuzumab antibodies.
Pharmacodynamic
PD markers including Notch1 target genes and cancer-stem cell biomarkers were evaluated in blood samples of 24 subjects and in paired tumor biopsies in one subject. Blood samples were collected at predosing and 7 days after the second and third dosing. Affymetrix human gene chip U133 Plus 2.0 arrays were used for profiling the gene expression levels in whole blood and tumor biopsies [Almac Diagnostics, Clinical Laboratory Improvement Amendments (CLIA) certified laboratory]. For further details on the PD analysis, refer to Supplementary Material, available at Annals of Oncology online.
Biomarker assessments
A CLIA-validated IHC analysis was carried out on available baseline tumor samples to determine NICD1 status (high or low) with an antibody that specifically recognizes an epitope generated by the terminal cleavage event in the formation of transcriptionally active intracellular Notch1 (Cell Signaling Technology Danvers, MA, clone D3B8). Tumors with an H-score ! 80 were defined as NICD1 high or Notch1 pathway activated. DNA sequencing was carried out on formalin-fixed paraffin embedded tumors by a targeted next generation sequencing panel (GeneDx) and/or cell-free DNA from blood (Guardant Health) to determine NOTCH1 mutation status.
Statistical analysis
The general analytical approach for evaluating all end points was descriptive in nature. No formal statistical hypothesis testing was conducted. Statistics describing time-to-event variables utilized the Kaplan-Meier method. All analyses and tabulations were carried out using SAS 
Results
Patient characteristics and drug exposure
Forty-eight subjects were enrolled at 5 US sites, all received at least one dose of brontictuzumab and were included in the safety and PK population. Patient demographics and baseline characteristics are listed in Table 1 . The dose escalation phase enrolled 33 subjects. The 1.5 mg/kg Q3W dose was selected as the MTD and an expansion cohort was opened at this dose level with 15 subjects with Notch1 pathway activation (NICD1 IHC high) enrolled. Overall, there were 22 NICD1 high and 19 NICD1 low. The median duration of drug exposure was two cycles (range 1-18), mean treatment duration was 56 days (range 1-365), and dose-intensity ranged from 46%-106% (mean 92.3%). In the expansion cohort, the median number of cycles was 3 (range 1-18), mean treatment duration was 89 days (range 1-365), and mean dose-intensity was 91.8% (range 60%-106%).
Safety
DLTs were reported for three subjects, one each in the 2.5 mg/kg Q4W, 2.5 mg/kg Q3W, and 2 mg/kg Q3W dose escalation cohorts. The DLTs were fatigue in one and diarrhea in two subjects, all grade 3. The number of DLTs in these cohorts did not exceed the threshold set for MTD, however, given the cumulative safety data, lower doses of brontictuzumab were tested and 1.5 mg/kg Q3W was considered tolerable.
Overall, 47 subjects (98%) had at least one TEAE. The most common were diarrhea (75%), fatigue (60%), nausea (46%), vomiting (29%), and AST increased (27%). Thirty-seven subjects (77%) had at least one TEAE that was ! grade 3 in severity. Forty-three subjects (90%) experienced TEAEs that were considered study drug-related. The most common were diarrhea (71%), fatigue (44%), nausea (40%), vomiting (21%), increase in AST (21%), and ALT (12%). Diarrhea was prolonged (!7 days duration) in 16 of 36 patients (44%) with a tendency of more prolonged episodes as treatment progressed, and in spite of aggressive management as per protocol. Nausea and vomiting were overall self-limited and responded to antiemetics, particularly ondansentron, while fatigue tended to be cumulative. Drugrelated AEs that occurred in !10% of subjects are listed in Table 2 .
Twenty-two (46%) subjects had at least one ! grade 3 study drug-related TEAE. Treatment-related ! grade 3 AEs occurred more frequently in higher dose cohorts (73% in ! 2 mg/kg cohorts; 0%-33% in <2 mg/kg). The most common ! grade 3 drug-related AE was diarrhea in 15 subjects (31%). Other ! grade 3 drug-related AEs that occurred in more than one subject included fatigue in four, ALT increase in two, and hypophosphatemia in two subjects. The most common reason for treatment discontinuation was disease progression in 31 subjects (65%). Brontictuzumab-related AEs resulting in study discontinuation included diarrhea in two subjects and ALT increase in an additional two subjects.
Serious TEAE were reported in 21 (44%) subjects, 4 of them (8%) were considered drug-related and consisted of grade 3 diarrhea in three subjects and colitis in one. The only grade 4 drugrelated AE reported was asymptomatic increase in lipase levels; there were no grade 5 TEAEs. All drug-related serious AEs occurred at dose levels !1.5 mg/kg. Seven (15%) subjects died within 30 days of last brontictuzumab treatment, five of progressive disease, one of respiratory failure, and one died in their sleep of unknown cause.
PK and immunogenicity
Brontictuzumab exhibited nonlinear pharmacokinetics. Average clearance decreased from 38 to 9 ml/day/kg as the dose level increased from 0.25 to 2.5 mg/kg. The average apparent terminal half-life of brontictuzumab ranged from 1 to 4 days. The volume of distribution at steady state maintained relative stability across dose levels. Complete drug washout was observed in all cohorts. The serum concentration-time profiles of brontictuzumab by cohort are presented in Figure 1 .
ADA was identified in four subjects predose at low titers, with increasing titers following study drug administration. Twentyseven subjects (56%) tested positive for ADA after the start of treatment, with emergence of positivity ranging from 19 to 97 days. The overall ADA prevalence was 65%. Multivariate time-series analysis was conducted to assess the impact of ADA formation on PK and safety. ADA formation over time had no correlation with change of clearance nor volume of distribution of brontictuzumab. The apparent high prevalence of ADA was likely the result of a very sensitive assay. Supplementary Table S1 , available at Annals of Oncology online describes PK parameters.
Efficacy
A total of 36 subjects including 21 NICD1 high were assessable for response assessment, 5 did not meet criteria for measurable lesion by RECIST. Two subjects (5%) had unconfirmed partial response (PR), 10 (28%) had stable disease (SD), and 24 (67%) had disease progression (PD). Clinical benefit rate defined as PR or SD for more than 6 months is outlined in Table 3 and Figure 2A . Percent change in the sum of tumor longest diameter by patient is displayed in Figure 2B . Both subjects who achieved a PR had ACC with high NICD1. Four patients had SD ! 6 months, 3 ACC and 1 CRC, all NICD1 high.
The median PFS was 65 days (95% CI 49-71 days). The DOR and PFS for the two ACC patients who achieved an unconfirmed PR were, respectively, 33 and 69 days for the first subject and censored for the second subject who discontinued the study due to grade 3 ALT increase after one dose of brontictuzumab. Seven subjects (15%) died and the remaining 41 (85%) were alive at the data cut-off, therefore, the median OS could not be estimated.
Pharmacodynamics
Expression of Notch1 target genes HES1 and HEY1 were modulated by brontictuzumab in blood showing target engagement (Figure 3 ). Notch1 and cancer stem-cell biomarkers were downregulated by brontictuzumab in paired tumor biopsies of a breast cancer subject (Supplementary Figure S1 , available at Annals of Oncology online). NOTCH1 activating mutations were identified in 4 of 45 subjects' samples (Supplementary Table S2 , available at Annals of Oncology online). All samples with NOTCH1 activating mutations were NICD1 high. G2  G3  G4/5 Total G1  G2  G3  G4/5 Total  G1  G2  G3  G4/5 Total  G1  G2  G3  G4/ 
Discussion
This was a first-in-human study of brontictuzumab, a monoclonal antibody targeting Notch1 in patients with solid tumors with anticipated Notch1 pathway activation. Brontictuzumab was generally well tolerated at the MTD, with treatment-related serious AEs experienced in 10% of subjects treated at 1.5 mg/kg Q3W. The main drug-related toxicity was diarrhea with 14 (29%) of them grade !3. Diarrhea is a known on-target effect of Notch inhibition, particularly Notch1 and 2 [7] , and was treated with standard antidiarrheal therapy and in some cases with somatostatin analogs with limited results. Notch inhibition promotes differentiation of intestinal epithelial progenitors cells into secretory cells causing a mucus-producing diarrhea [9] . As predicted by this mechanism, we observed late onset diarrhea 14-21 days after brontictuzumab treatment. Symptoms were persistent, despite the relatively short brontictuzumab half-life and aggressive management. Since brontictuzumab specifically inhibits Notch1, we expected the incidence of diarrhea to be lower than what has been reported with GSIs; however, the frequency and grade of diarrhea observed was comparable with that reported with GSI [10] [11] [12] , suggesting that Notch1 is the main pathway involved in intestinal cell differentiation and its inhibition is sufficient to induce clinically significant goblet cell metaplasia. Other less common grade 3 treatment-related AEs were fatigue (8%), ALT increase (4%), and hypophosphatemia (4%). Only one grade 4 drug-related AE was reported (asymptomatic lipase increase).
Antitumor activity was observed in two subjects who achieved an unconfirmed PR, and in four with prolonged SD (!6 months), all of them NICD1 high. In an exploratory analyses, the longest range of PFS and OS was observed in ACC subjects with NICD1 high. Details on prior therapy lines and outcomes of ACC patients treated in this study are outlined in Supplementary  Table S3 , available at Annals of Oncology online.
Activating NOTCH1 mutations occur in up to 33% of ACC patients with metastatic disease [13] . They are associated with an aggressive disease phenotype, higher incidence of liver and bone metastasis, and worse clinical outcomes [4] . Notch1 pathway activation was observed in 83% of ACC patients screened for this study (19 of 23) , but only four had NOTCH1 mutations. These ACC patients represented the entire NOTCH1 mutant population that participated in the study [4, 14] . The mechanism of Notch1 pathway activation in the NOTCH1 wild-type tumors, such as mutations in other genes predicted to activate the Notch pathway (e.g. SPEN, FBXW7), or epigenetic modifications was not explored.
The clinical course of one of the ACC patients who was treated under this clinical study and achieved a PR and unequivocal clinical benefit has been published [4] . This specific patient was the only subject with at least two co-occurring NOTCH1 activating mutations before treatment initiation, one in the NRR and one in the PEST domain (L1600Q, S2467fs*). Interestingly, in the original report by Weng et al [2] describing NOTCH1 mutations as oncogenic drivers in T-ALL, cell lines with NRR and PEST comutations were the most sensitive to GSI. The presence of HD and PEST domain mutations activate Notch1 pathway synergistically and suggests NOTCH1 oncogene addiction. All other NOTCH1 mutations identified in our study subjects occurred exclusively in the PEST domain (Supplementary Table S2 , available at Annals of Oncology online), which is ligand-dependent (nonconstitutive) and promotes weaker Notch1 signaling [1] .
Intriguingly, the second ACC patient who achieved a PR had a RUNX1 mutation (R232L). RUNX is a transcription factor that serves as a master regulator of development. Its function is linked to other major developmental pathways including Notch1. The oncogenic activity of this genomic alteration is unknown, however, mutations is RUNX1 is known to be oncogenic in leukemias [15] .
Besides the shared diagnosis of ACC in the two responders, both experienced hepatic toxicity (asymptomatic increase in transaminases), which led to treatment discontinuation. In preclinical toxicology experiments with brontictuzumab in mokeys, microscopic sinusoidal dilation was noted, but it did not lead to an increase in transaminases. Notch1 and Jag1 are known to be involved in hepatocytes and liver vasculature regeneration, which could be involved in the pathogenesis of the liver toxicity noted [16, 17] .
Despite pharmacodynamic evidence of brontictuzumab ontarget activity, the suppression of Notch1 target genes in the blood was modest in patient's treated at the MTD, which together with the drug short half-life, could have impacted the clinical activity of brontictuzumab.
Except for desmoid tumors, a neoplasm with known Wnt pathway activation and crosstalk with Notch signaling, the activity of GSI has been limited in phase I studies including unselected solid tumor types [11, [18] [19] [20] [21] [22] [23] . Compared with the GSI trials reported to date, our study with brontictuzumab was unique to use a biomarker test (NICD1 IHC) to select patients for the expansion cohort and was the first to enroll ACC.
In spite of its signal of single agent activity in ACC and the encouraging preclinical results of Notch inhibitors in combination with chemotherapy or targeted therapy [24] [25] [26] [27] , brontictuzumab drug development has been discontinued.
Conclusion
In conclusion, brontictuzumab MTD was 1.5 mg/kg Q3W. Diarrhea was the most common treatment-related AE. An efficacy signal was noted in the ACC subgroup with Notch1 pathway activation. Patient selection based on NOTCH1 mutation status and combination of brontictuzumab with other antineoplastic agents might lead to improved clinical benefit. 
